AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03368417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wireless HBPM System
Description: BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control.
Study NCT03368417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP Monitoring Incentives
Description: Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~* Participants receive SGD 3 for each day they measure their BP, up to three times per week.~* Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~* Participants receive an initial health capital of SGD 72~* Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading.
Study NCT01821313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Study NCT01821313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Exercise
Study NCT03307135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single assessment with the MSPMI
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
Study NCT03307135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double assessment with the MSPMI with 7 days of interval
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
Study NCT03307135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double assessment with the MSPMI before and after treatment
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
Study NCT05660876 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard fistulotomy
Description: in a standard manner fistula tract was identified and laid open without doing marsupialization
Study NCT05660876 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fistulotomy with marsupialization
Description: in this arm fistulotomy was done in a standard manner and marsupialization was done
Study NCT04044937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoroethyltyrosine (FET)
Description: Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
Study NCT04044937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
Study NCT01114555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Irinotecan and Temozolomide
Description: Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
Study NCT03318172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
Study NCT03318172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
Study NCT03396562 — intervention group
Intervention type: OTHER
Intervention: Assessments of Development and Growth
Description: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
Study NCT00472238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: endurance training
Description: control group.
Study NCT00472238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Treadmill exercise training to optimize physical endurance
Study NCT02708056 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sugammadex
Study NCT03903146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Childhood Obesity Risk-Reduction Program in Hispanics
Description: Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month).
Study NCT04292223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
Study NCT01401166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
Study NCT01401166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
Study NCT01401166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Use Injection Device
Description: The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
Study NCT01134705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Study NCT01134705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: HFA Vehicle Aerosol
Study NCT01401166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Use Injection Device
Description: The SID will be used, containing Herceptin 600 mg per 5 mL.
Study NCT01789268 — intervention group
Intervention type: DEVICE
Intervention: Respiratory Inductive Plethysmography
Description: Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
Study NCT03200223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized healthcare service
Description: Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
Study NCT02750293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D preparation
Study NCT02750293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05081687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: 5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
Study NCT03806816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
Study NCT03806816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO group
Description: 5 daily enteral doses of placebo 2 ml/kg
Study NCT02952417 — intervention group
Intervention type: OTHER
Intervention: Excess mortality
Description: Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
Study NCT03062371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playgroup
Description: A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
Study NCT04600037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
Study NCT01555814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: 4-week open label amisulpride treatment
Study NCT04985162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Differential learning based physiotherapy to improve torso control, balance and gait
Study NCT04985162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Ordinary physiotherapy program
Study NCT01513590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec/insulin aspart
Description: Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
Study NCT01513590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
Study NCT01658839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.004% (new formulation)
Description: Travoprost ophthalmic solution, 0.004%, new formulation
Study NCT03421587 — intervention group
Intervention type: BEHAVIORAL
Intervention: Processing of social olfactory and tactile stimuli
Description: Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
Study NCT04892160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guided Imagery
Description: Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
Study NCT04892160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
Study NCT04892160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality
Description: Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
Study NCT04892160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
Study NCT03704077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Specified dose on specified days
Study NCT03704077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03704077 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03704077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT03704077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT03704077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Specified dose on specified days
Study NCT01167244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Study NCT00977119 — intervention group
Intervention type: OTHER
Intervention: Side-effect questionnaires
Description: Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
Study NCT00977119 — intervention group
Intervention type: OTHER
Intervention: research blood samples
Description: Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
Study NCT03144232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
Study NCT03144232 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
Study NCT01404481 — intervention group
Intervention type: DEVICE
Intervention: clean intermittent self catheterisation single use vs re use
Description: Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
Study NCT04239378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation
Description: Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
Study NCT02833909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT04239378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat small
Description: Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat small placebo
Description: Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat large
Description: Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat large placebo
Description: Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
Study NCT02969655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa placebo
Description: Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
Study NCT04226157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring Device (Qardio Arm)
Description: The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
Study NCT04226157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Provider Blood Pressure Management
Description: Participant will follow up as would normally do with primary care provider for blood pressure management.
Study NCT04547699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK